Advantage Alpha Capital Partners’s Protagonist Therapeutics PTGX Stock Holding History

Advantage Alpha Capital Partners’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,804	Closed	-$386K	–	89
2025 Q3	$386K	Sell	5,804 -1,168	-17%	-$66.4K	0.12%	114
2025 Q2	$385K	Sell	6,972 -1,662	-19%	-$79.8K	0.1%	106
2025 Q1	$418K	Buy	8,634 +2,892	+50%	+$121K	0.1%	100
2024 Q4	$222K	Sell	5,742 -5,594	-49%	-$244K	0.05%	144
2024 Q3	$510K	Buy	+11,336	New	+$458K	0.12%	117

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Advantage Alpha Capital Partners's PTGX Position: Q4 2025 in Review

Advantage Alpha Capital Partners sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 5,804 shares — an estimated $386K sold.

Advantage Alpha Capital Partners first reported a position in PTGX in Q3 2024 and held it in 5 quarters. The position peaked at $510K in Q3 2024. 315 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

Advantage Alpha Capital Partners reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
Advantage Alpha Capital Partners sold 5,804 Protagonist Therapeutics shares in Q4 2025, an estimated $386K.
Advantage Alpha Capital Partners first reported a position in Protagonist Therapeutics in Q3 2024 and held it in 5 quarters.
Advantage Alpha Capital Partners's Protagonist Therapeutics position peaked at $510K in Q3 2024.
315 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on Advantage Alpha Capital Partners's 13F filing for Q4 2025.